Search results
Results from the WOW.Com Content Network
A parasympathomimetic drug, sometimes called a cholinomimetic drug [1] or cholinergic receptor stimulating agent, [2] is a substance that stimulates the parasympathetic nervous system (PSNS).
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML [1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. [2]
Antipsychotics, previously known as neuroleptics [1] and major tranquilizers, [2] are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders.
Physostigmine, an acetylcholinesterase inhibitor, can be used to treat glaucoma and delayed gastric emptying.Because it enhances the transmission of acetylcholine signals in the brain and can cross the blood–brain barrier, physostigmine salicylate is used to treat anticholinergic poisoning (that is, poisoning by substances that interfere with the transmission of acetylcholine signaling, such ...
OTC Bayer medication with child-resistant packaging (cap) and tamper-resistant carton and innerseal Photo of the packaging of four medicines dispensed in the United Kingdom showing their Product Licence Numbers and symbols denoting if they are Prescription Only Medicine (POM) or Pharmacy Medicine (P), or lacking either, denoting General Sales List (GSL).
Agents in common clinical use include: [1] [2] Prostaglandin analogs; Parasympathomimetic (miotic) agents, including cholinergic and anticholinesterase agents; Carbonic anhydrase inhibitors (oral and topical)
This page was last edited on 5 November 2019, at 17:10 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
This article needs to be updated.The reason given is: the section related to E.U. needs further updates (esp. in sections 3.2 and 4.2.2) as the directives 93/42/EEC on medical devices and 90/385/EEC on active implantable medical devices have been fully repealed on 26 May 2021 by Regulation (EU) no. 2017/745 (MDR); furthermore, Brexit triggers updates in these sections (U.K. developed their own ...